Emergent BioSolutions Inc.
EBS
$5.63
-$0.25-4.25%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 317.25% | -127.26% | 140.55% | -3,245.56% | 118.18% |
| Total Depreciation and Amortization | -2.31% | -1.52% | -7.37% | 2.15% | -5.74% |
| Total Amortization of Deferred Charges | 4.55% | 132.84% | -234.00% | -27.54% | 21.05% |
| Total Other Non-Cash Items | 38.82% | 118.32% | -150.88% | 1,124.72% | -354.29% |
| Change in Net Operating Assets | -39.16% | -230.03% | -68.14% | 311.18% | -327.80% |
| Cash from Operations | 85.98% | -151.98% | 223.58% | 175.88% | -295.02% |
| Capital Expenditure | -111.76% | 70.69% | -26.09% | 57.41% | 5.26% |
| Sale of Property, Plant, and Equipment | 12,600.00% | -96.05% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -100.00% | -- | -- | -- |
| Other Investing Activities | -16.67% | -- | -- | -- | -- |
| Cash from Investing | 108.04% | -74.46% | 2,534.78% | 57.41% | 5.26% |
| Total Debt Issued | -- | -100.00% | 1,360.00% | -70.00% | 150.00% |
| Total Debt Repaid | -- | 100.00% | -582.64% | -579.78% | 44.03% |
| Issuance of Common Stock | -87.50% | -91.40% | 1,228.57% | -- | -- |
| Repurchase of Common Stock | -66.67% | 0.00% | -50.00% | 50.00% | -300.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | 179.66% | -- | -- |
| Cash from Financing | -180.00% | 100.28% | -254.22% | -225.06% | 765.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 192.91% | -159.48% | 1,167.50% | 75.54% | -236.82% |